Drug Profile
TTI 101
Alternative Names: C-188-9; TTI-101Latest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Baylor College of Medicine
- Developer Tvardi Therapeutics
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Naphthalenes; Small molecules; Sulfonamides
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HER2 negative breast cancer; Idiopathic pulmonary fibrosis; Liver cancer
- Phase I/II Pancreatic cancer
- Phase I Solid tumours
- Preclinical Fibrosis; Inflammation
Most Recent Events
- 16 Jan 2024 Phase-I/II clinical trials in Pancreatic cancer in USA (PO) (NCT06141031)
- 21 Nov 2023 University of Colorado in collaboration with Tvardi Therapeutics plans a phase I/II trial for Pancreatic cancer (Second-line therapy or greater) in USA (PO, Tablet) (NCT06141031)
- 03 Aug 2023 Chemical structure information added